Merck’s new, once-weekly experimental type 2 diabetes treatment was found in recent clinical trials to have a similar safety and efficacy profile compared to Merck’s sitagliptin, marketed under the brand name Januvia. The study involving the new omarigliptin randomly assigned participants with type 2 diabetes into one of three groups – once-weekly omarigliptin 25 mg; once-daily Januvia 50 mg; or placebo. A mixed-meal tolerance test was performed the day before the study drugs were administered and again at 24 weeks, 1 day after the last dose of Januvia, or 7 days after the last dose of omargliptin. Researchers found that ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.